The preparation is commonly used for supportive symptomatic management in conditions marked by temporary physiological stress, providing assistance across domains where additional symptomatic support is needed. The therapeutic approach involves supportive care relevant to its use for symptoms of functional strain. The primary active component is generally used to help enhance physical capacity and reduce mental fatigue in situations of stress.

It is relevant for addressing symptom clusters that include physical weakness, persistent tiredness, mental fatigue, and reduced alertness. It is commonly used in clinical scenarios like convalescence (the recovery phase after a prolonged illness) and during periods of high functional demand.

“It supports the body in situations involving temporary systemic imbalance, may assist with supporting functional stability.”

Quick Fact: Relief for Mental and Physical Fatigue

This supportive care may help patients cope more steadily with symptom fluctuations, which contributes to easing the overall symptom load and supports general well-being.

Regulatory References

1. Health Canada Monograph on Panax Ginseng

This section outlines the officially documented population eligibility and restrictions for Фарматон (Pharmaton Vitality Capsules), based strictly on government regulatory documents.

Eligibility Scope

Classification	Eligible or Non-Eligible Populations
Allowed Use	Adult men and women (general use population).
Not Recommended	Children (pediatric population).

Contraindications and Restrictions

The medicine is formally contraindicated (must not be used) in the following groups:

• Pregnancy and Lactation: Women who are pregnant or breastfeeding.
• Organ Function: Patients with renal insufficiency (kidney impairment).
• Overload Risk: Patients with Hypervitaminosis A or D, or those with haemochromatosis or iron overload syndrome.
• Metabolic Disorders: Patients with disturbances of calcium metabolism (e.g., hypercalcaemia).
• Concurrent Treatment: Patients receiving concomitant retinoid therapy (e.g., for acne) or vitamin D therapy.
• Allergies: Patients with known allergy to Peanut Oil (Arachis Oil) or Soya (due to a possible cross-allergy).

Connection to the Overall Eligibility Profile

The regulatory profile strictly limits the use of Фарматон to the adult population. The contraindications are primarily driven by the product’s high levels of fat-soluble vitamins (A and D) and Iron, ensuring the exclusion of populations facing risks of systemic overload, organ impairment, or specific hypersensitivities.

Interactions with other medicines and products — official regulatory information for Фарматон

---

Interaction Scope

Property	Description (Strictly Regulatory)
Medicinal product categories with documented interactions	Coumarin anticoagulants; Antihypertensives; Central Nervous System ( CNS) agents; Levodopa-containing products; Insulin.
Specific interacting medicines (if explicitly listed)	Warfarin; Levodopa; Insulin.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic antagonism (Ginseng); Interference with absorption via chelation (Iron component).
Timing-based interaction rules (if applicable)	Required separation of administration times for medicines sensitive to chelation by metal ions, such as Levodopa.
Population-specific interaction notes (if applicable)	Increased INR monitoring is required for patients taking Warfarin; Adjustment of control is required for diabetic patients taking Insulin.
Interaction-related restrictions	The oral solution formulation contains alcohol and is restricted for use by drivers or machine handlers; the capsule form is recommended as an alternative.

Interaction Classifications (High-Level)

Property	Description (Strictly Regulatory)
Interaction severity classification (as defined in official documents)	Clinically significant interactions requiring mandatory monitoring or adjusted administration; No contraindicated combinations are explicitly listed in the regulatory labeling.
Regulatory basis (EMA / FDA / etc.)	National and European regulatory authorities (e.g., HPRA, EMA).
Interaction-context constraints (as defined in official documents)	Procedural constraints requiring monitoring adjustments or timing separation for co-administered substances.

Resulting Interaction Structure

Official interaction statements:

• The Panax Ginseng G115 extract may reduce the effect of Warfarin, necessitating increased monitoring of INR levels when the product is initiated or discontinued.
• The Iron component can interfere with the absorption of Levodopa, requiring separation of administration times.
• Ginseng may potentiate the effect of antihypertensives and may affect the activity of CNS depressant or stimulant drugs.
• The product may permit a reduction of Insulin dosage in diabetic patients, which mandates adjustment of diabetes control.

Connection to the overall interaction profile (2–4 sentences):

The regulatory documents define the product's interaction structure around the pharmacodynamic effects of the Panax Ginseng G115 extract and the absorption interference caused by the mineral component. This structure results in mandated procedural constraints, specifically increased monitoring requirements for patients on anticoagulants and timing separation rules for certain other medicines, rather than broad contraindications. The official profile is strictly descriptive of these documented outcomes and monitoring requirements.

How Фарматон Works

Modulation of Receptor- and Enzyme-Mediated Signaling

Фарматон acts within mechanistic domains involving receptor- or enzyme-mediated signaling to influence cell-to-cell communication. It engages specific molecular targets to either initiate or suppress signaling sequences, resulting in modified systemic physiological outcomes.

---

Influence on Dysregulated Signaling Pathways

The drug engages mechanisms that influence systems where targeted pathway adjustment is required, modulating processes driven by distinct signaling patterns. This action modifies the functional status of targeted biological pathways, which affects the concentration and duration of mediator activity.

---

Effect on Intracellular Signaling Cascades

Фарматон modifies early molecular steps within complex signaling cascades that shape systemic physiological outcomes. By influencing feedback regulation within pathways, it counteracts heightened activity within specific physiological systems, resulting in defined changes in physiological parameters.

Official Administration Guidelines

Фарматон (Pharmaton) is a composite multivitamin, mineral, and standardized Panax Ginseng (G115) supplement. Its administration is standardized to ensure consistent usage.

---

Dosing Schedule and Route

Field	Instruction
Route of administration	The medicine is taken exclusively via the oral route in the form of a capsule or tablet.
Dosing schedule	The standard dose for adults (including the elderly) is one capsule or tablet daily.
Maximum Dose	The recommended daily dose of one unit must not be exceeded.

---

Procedural and Timing Instructions

Field	Instruction
Frequency	The dose should be taken once daily.
Timing in relation to meals	It is recommended that the dose be taken with food, preferably with the morning meal (breakfast), to simplify adherence and optimize absorption.
Preparation	The capsule or tablet must be swallowed whole with water. It must not be crushed or chewed.
Missed Dose	If a dose is missed, the user should continue the regular schedule the following day; do not double the dose to compensate for the missed unit.

---

Course Duration and Restrictions

• Treatment Course: Use should begin with a course of 4 weeks. If symptoms improve, the course may be continued for up to 12 weeks.
• Long-Term Use: Continued use of Фарматон beyond the 12-week period requires consultation with a healthcare professional, as they may wish to investigate symptoms further.
• Pediatric Use: The preparation is not suitable for children and is only approved for use in adults.

Research evidence / Overview of studies for Фарматон

Evidence for use in Temporary Fatigue, Exhaustion, and Weakness

Clinical research available in the broader evidence landscape includes Randomized Controlled Trials (RCTs)—some of which were double-blind and placebo-controlled—alongside systematic reviews and meta-analyses. Studies have examined perceived changes in general fatigue and levels of tiredness in adult populations experiencing temporary periods of fatigue, weakness, or stress.

The combination was studied for its use during convalescence (the phase after a prolonged illness) and in research monitoring physiological strain or stress in individuals experiencing general weakness. Some controlled trials data show patterns related to subjective mental and physical performance when compared to the placebo group. Some regulatory bodies included documentation relating to the product's Traditional Use (long-standing use) when defining the scope for the general indication of weakness and tiredness.

Outcomes Measured in Clinical Research

Researchers have focused on patient-reported outcomes describing perceived discomfort rather than clinical disease. Trials applied in studies examining patient-reported experiences primarily looked at outcomes related to systemic or functional imbalance, particularly subjective feelings of exhaustion. This included using specific scales to measure General, Mental, and Physical Fatigue levels. Furthermore, studies explored patient reports regarding overall Health-Related Quality of Life (QoL) and examined metrics related to Cognitive Function and Mental Performance. Findings help contextualize how patients reported their experience during the study periods.

Study Duration and Long-term Follow-up

Long-term effects are not fully established. The majority of clinical studies that have explored short-term symptom changes used observation periods of short to intermediate duration, most commonly ranging from 2 weeks up to 3 months (90 days). Data addressing extended use over many months are still emerging.

The Quality and Limitations of the Evidence

The overall evidence quality varies across studies, leading regulatory bodies and systematic reviews to draw cautious conclusions. Limitations include the modest sample sizes often used in trials and the fact that follow-up durations were limited to only a few months. The inconsistent findings across the entire evidence base contribute to a situation where the overall level of certainty remains low for this general indication.

Common questions about Фарматон (FAQ)

Q: Does this medicine interact with other vitamins or minerals?

Official product information advises users to consider the total daily intake of all vitamins and minerals from every source, including food and other supplements. This is necessary to avoid exceeding safe levels of components like Vitamin A, Vitamin D, and Iron. Information regarding all supplements and nutrient intake should be reviewed with a healthcare professional.

Q: What are the most common side effects of the supplement?

Regulatory documents report that side effects classified as common (meaning they affect fewer than 1 in 10 people) may include nausea, vomiting, and headache. These reactions are typically mild and temporary. The product information states that taking the capsule with food may help minimize the risk of these gastrointestinal effects, and the label recommends administration with a meal.

Q: What is the time of day I should take my dose?

Official administration instructions recommend taking the daily dose in the morning, along with food. This suggested timing is based on simplifying adherence for the user. The product information recommends taking the daily dose with food in the morning, which aligns with the standard administration advice found on the label.

Q: What are the signs or symptoms of an overdose?

Regulatory safety information highlights that the product contains iron, which can be dangerous if taken in excess. In the specific event that a child accidentally swallows a capsule, the product label warns that this requires immediate medical attention. If an overdose is suspected, it is critical to seek emergency medical attention.

How to Store and Dispose of Фарматон?

The storage and disposal of this product are defined by official regulatory requirements to ensure its stability and protect public safety.

Mandatory Storage Requirements

Condition	Official Requirement
Temperature	Do not store above 25 C.
Protection	Protect from moisture.
Container Rule	Keep the bottle tightly closed.
Shelf-Life	Do not use after the printed expiry date (EXP).

Child Safety

The product must be kept out of the sight and reach of children as a mandatory safety measure.

Official Disposal Instructions

Regulatory instructions prohibit discarding unused or expired capsules via household waste or by flushing them into wastewater systems. Users are required to consult with a pharmacist for guidance on the proper, environmentally compliant method for disposing of unwanted medicines.